Cover Image
市場調查報告書

Gilead Sciences, Inc.的產品平台分析

Gilead Sciences, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 240924
出版日期 內容資訊 英文 138 Pages
訂單完成後即時交付
價格
Back to Top
Gilead Sciences, Inc.的產品平台分析 Gilead Sciences, Inc. - Product Pipeline Review - 2016
出版日期: 2016年03月16日 內容資訊: 英文 138 Pages
簡介

本報告提供Gilead Sciences, Inc.的治療藥開發平台現狀與各開發階段的比較分析,藥物標的,作用機制,給藥途徑,各分子類型治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Gilead Sciences, Inc.的基本資料

Gilead Sciences, Inc.概要

  • 主要資訊
  • 企業資料

Gilead Sciences, Inc.:R&D概要

  • 主要的治療範圍

Gilead Sciences, Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Gilead Sciences, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Gilead Sciences, Inc.:藥物簡介

  • (cobicistat + darunavir)
  • (ledipasvir + sofosbuvir)
  • cobicistat
  • elvitegravir
  • idelalisib
  • sofosbuvir
  • tenofovir disoproxil fumarate
  • ambrisentan
  • momelotinib
  • nimotuzumab
  • ranolazine ER
  • tenofovir alafenamide
  • (ranolazine + dronedarone)
  • (Sofosbuvir + GS-5816)
  • GS-4774
  • GS-5806
  • GS-6615
  • GS-9256
  • GS-9669
  • GS-9973
  • regadenoson
  • simtuzumab
  • tegobuvir
  • vedroprevir
  • GS-4997
  • GS-5737
  • GS-5745
  • GS-9620
  • GS-9857
  • AB-0045
  • GS-607601
  • GS-8374
  • GS-967
  • GS-563253等

Gilead Sciences, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Gilead Sciences, Inc.:最近的開發平台趨勢

Gilead Sciences, Inc.:暫停中的計劃

Gilead Sciences, Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • adefovir dipivoxil
    • ambrisentan
    • aztreonam
    • cicletanine
    • clevudine
    • Darusentan
    • dexelvucitabine
    • emivirine
    • enoximone
    • fentanyl citrate
    • GS-9005
    • GS-9132
    • GS-9667
    • PSI-938
    • tesmilifene hydrochloride

Gilead Sciences, Inc.:企業發表

Gilead Sciences, Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07983CDB

Summary

Global Markets Direct's, 'Gilead Sciences, Inc. - Product Pipeline Review - 2016', provides an overview of the Gilead Sciences, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Gilead Sciences, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Gilead Sciences, Inc.
  • The report provides overview of Gilead Sciences, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Gilead Sciences, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Gilead Sciences, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Gilead Sciences, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Gilead Sciences, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Gilead Sciences, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Gilead Sciences, Inc. Snapshot
    • Gilead Sciences, Inc. Overview
    • Key Information
    • Key Facts
  • Gilead Sciences, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Gilead Sciences, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • Gilead Sciences, Inc. - Pipeline Products Glance
  • Gilead Sciences, Inc. - Late Stage Pipeline Products
  • Gilead Sciences, Inc. - Clinical Stage Pipeline Products
  • Gilead Sciences, Inc. - Early Stage Pipeline Products
  • Gilead Sciences, Inc. - Drug Profiles
    • (emtricitabine + rilpivirine hydrochloride + tenofovir alafenamide)
    • (emtricitabine + tenofovir alafenamide fumarate)
    • (sofosbuvir + velpatasvir)
    • tenofovir alafenamide
    • (cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide fumarate)
    • (emtricitabine + GS-9883 + tenofovir alafenamide)
    • (GS-9857 + sofosbuvir + velpatasvir)
    • ambrisentan
    • eleclazine
    • GS-5745
    • idelalisib
    • momelotinib dihydrochloride
    • acalisib
    • entospletinib
    • GS-4774
    • presatovir
    • ranolazine ER
    • regadenoson
    • selonsertib
    • selonsertib + simtuzumab
    • simtuzumab
    • vesatolimod
    • GS-5829
    • GS-5734
    • GS-9674
    • GS-9876
    • ONO-4059
    • GS-459679
    • GS-548202
    • GS-5759
    • GS-607601
    • GS-8374
    • GS-967
    • GS-986
    • Monoclonal Antibodies 1 for Oncology
    • Monoclonal Antibody for HIV / AIDS
    • Monoclonal Antibody to Target HIV-Envelope and CD3 for HIV
    • Px-103
    • Small Molecule to Inhibit Histone Deacetylation for Oncology
    • Small Molecule to Inhibit Histone Methyltransferase for Oncology
    • GS-563253
    • GS-599220
    • Small Molecule for RSV
    • Small Molecule to Inhibit NS4B Protein for HCV
    • Small Molecules for Hepatitis C Infection
    • Small Molecules to Inhibit NS3 Protease for Hepatitis C
    • Small Molecules to Inhibit NS5B for Hepatitis C
  • Gilead Sciences, Inc. - Pipeline Analysis
  • Gilead Sciences, Inc. - Pipeline Products by Target
  • Gilead Sciences, Inc. - Pipeline Products by Route of Administration
  • Gilead Sciences, Inc. - Pipeline Products by Molecule Type
  • Gilead Sciences, Inc. - Pipeline Products by Mechanism of Action
  • Gilead Sciences, Inc. - Recent Pipeline Updates
  • Gilead Sciences, Inc. - Dormant Projects
  • Gilead Sciences, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Gilead Sciences, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Gilead Sciences, Inc., Key Information
  • Gilead Sciences, Inc., Key Facts
  • Gilead Sciences, Inc. - Pipeline by Indication, 2016
  • Gilead Sciences, Inc. - Pipeline by Stage of Development, 2016
  • Gilead Sciences, Inc. - Monotherapy Products in Pipeline, 2016
  • Gilead Sciences, Inc. - Combination Treatment Modalities in Pipeline, 2016
  • Gilead Sciences, Inc. - Partnered Products in Pipeline, 2016
  • Gilead Sciences, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Gilead Sciences, Inc. - Out-Licensed Products in Pipeline, 2016
  • Gilead Sciences, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Gilead Sciences, Inc. - Pre-Registration, 2016
  • Gilead Sciences, Inc. - Phase III, 2016
  • Gilead Sciences, Inc. - Phase II, 2016
  • Gilead Sciences, Inc. - Phase I, 2016
  • Gilead Sciences, Inc. - Preclinical, 2016
  • Gilead Sciences, Inc. - Discovery, 2016
  • Gilead Sciences, Inc. - Pipeline by Target, 2016
  • Gilead Sciences, Inc. - Pipeline by Route of Administration, 2016
  • Gilead Sciences, Inc. - Pipeline by Molecule Type, 2016
  • Gilead Sciences, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Gilead Sciences, Inc. - Recent Pipeline Updates, 2016
  • Gilead Sciences, Inc. - Dormant Developmental Projects,2016
  • Gilead Sciences, Inc. - Discontinued Pipeline Products, 2016
  • Gilead Sciences, Inc., Other Locations
  • Gilead Sciences, Inc., Subsidiaries

List of Figures

  • Gilead Sciences, Inc. - Pipeline by Top 10 Indication, 2016
  • Gilead Sciences, Inc. - Pipeline by Stage of Development, 2016
  • Gilead Sciences, Inc. - Monotherapy Products in Pipeline, 2016
  • Gilead Sciences, Inc. - Combination Treatment Modalities in Pipeline, 2016
  • Gilead Sciences, Inc. - Partnered Products in Pipeline, 2016
  • Gilead Sciences, Inc. - Out-Licensed Products in Pipeline, 2016
  • Gilead Sciences, Inc. - Pipeline by Top 10 Target, 2016
  • Gilead Sciences, Inc. - Pipeline by Route of Administration, 2016
  • Gilead Sciences, Inc. - Pipeline by Molecule Type, 2016
  • Gilead Sciences, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top